Loading...
Loading...
Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd. Spoken Alpha tracks HKPD's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks HKPD's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for HKPD.
curl https://api.spokenalpha.com/v1/companies/HKPD| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.98 | $0.82 | +19.9% | +3.6% | +0.8% |
| Q4 FY2026 | $1.41 | $1.10 | +28.6% | +7.6% | +6.8% |
| Q3 FY2026 | $1.16 | $1.00 | +16.4% | +7.3% | +6.6% |
| Q2 FY2026 | $1.03 | $0.89 | +16.2% | -3.8% | -2.8% |
| Q1 FY2025 | $1.36 | $1.16 | +17.5% | +7.0% | +9.9% |
| Q4 FY2025 | $1.17 | $1.00 | +16.8% | -0.7% | -0.2% |
| Q3 FY2025 | $1.45 | $1.15 | +25.7% | +0.3% | +1.9% |
| Q2 FY2025 | $1.39 | $1.06 | +30.9% | -1.6% | -0.7% |
| Q1 FY2024 | $1.41 | $1.11 | +26.7% | -1.4% | -4.3% |
| Q4 FY2024 | $1.48 | $1.17 | +26.1% | -3.9% | -6.3% |